Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Time, And Price, Are Right To Prescribe Statins To the Masses

Dec 02 2013

• By Emily Hayes

Related Content

FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins

Dec 17 2007

Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol

May 14 2012

Bad News/Good News For Cholesterol: Another Strike Against HDL, But Support For Stricter LDL Targets

May 21 2012

Today’s Statin Debate Bears Lessons For Tomorrow’s Cholesterol Drugs

Apr 23 2012

Other CETP Inhibitors Could Escape Torcetrapib Trap, ACC Studies Suggest

Apr 02 2007

Branded Life After <em>Lipitor</em>: Pharma Targets Unmet Needs In Dyslipidemia

Apr 23 2012

SEARCH Ends Badly For Simvastatin 80 Mg; FDA Restricts Use To Existing Patients

Jun 08 2011

Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends

Nov 13 2013

FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study

Oct 30 2013

Related Companies

AstraZeneca PLC

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Pfizer Inc.

Bayer AG

Merck & Co., Inc.

AbbVie Inc.

Amarin Corp plc

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window